Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 3, 2014, Pages

  Blaslov, Kristina ^a   Zibar, Karin ^a   Bulum, Tomislav ^a   Duvnjak, Lea ^a  

^a University of Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; EXENDIN 4; FAT; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; TRIACYLGLYCEROL; VENOM;

ADULT; AGED; BLOOD CELL COUNT; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; FAT CONTENT; FEMALE; HUMAN; LETTER; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PLEIOTROPY; WAIST CIRCUMFERENCE; BLOOD; BODY MASS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; MIDDLE AGED;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PEPTIDES; TRIGLYCERIDES; VENOMS; WAIST CIRCUMFERENCE;

EID: 84902543935     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.10.013     Document Type: Letter

References (9)

1. Williamson R.M., Glancy S., Perry E., et al. Prevalence and risk factors for hepatic steatosis and non-alcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 2011, 34:1139-1144.
2. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in non-alcoholic fatty liver disease. Gastroenterology 2005, 128(7):1898-1906.
3. Zelber-Sagi S., Webb M., Assy N. Comparison of fatty liver index with non-invasive methods for steatosis detection and quantification. World J Gastroenterol 2013, 19(1):57-64.
4. Holst J.J., Vilsbøll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009, 297(1-2):127-136.
5. Cuthbertson D.J., Irwin A., Gardner C.J., et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given Glucagon-like Peptide-1 (GLP-1) receptor agonists. PLoS One 2012, 7(12):e50117.
6. Gupta N.A., Mells J., Dunham R.M., et al. Glucagon-like Peptide-1 Receptor (GLP-1R) is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51(5):1584-1592.
7. Klonoffa D.C., Buseb J.B., Nielsenc L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24(1):275-286.
8. Sathyanarayana P., Jogi M., Muthupillai R., et al. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 2011, 19:2310-2315. [PMID: 21660077].
9. Samson S.L., Gonzalez E.V., Yechoor V., et al. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther 2008, 16:1805-1812.